Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis.


Journal

Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003

Informations de publication

Date de publication:
Historique:
entrez: 14 7 2021
pubmed: 15 7 2021
medline: 15 7 2021
Statut: epublish

Résumé

[This corrects the article DOI: 10.1093/noajnl/vdaa082.].

Identifiants

pubmed: 34258581
doi: 10.1093/noajnl/vdab095
pii: vdab095
pmc: PMC8272530
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

vdab095

Commentaires et corrections

Type : ErratumFor

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Auteurs

Iyad Alnahhas (I)

Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Mouaz Alsawas (M)

Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.

Appaji Rayi (A)

Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Joshua D Palmer (JD)

Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Raju Raval (R)

Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Shirley Ong (S)

Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Pierre Giglio (P)

Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Mohammad Hassan Murad (MH)

Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.

Vinay Puduvalli (V)

Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Classifications MeSH